TYPE 1 DIABETES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On March 14, 2023, Lexicon Pharmaceuticals, a biopharmaceutical company, announced that it will resubmit a New Drug Application (NDA) to the U.S. FDA for approval of sotagliflozin to enhance glycemic control in type 1 diabetes patients with chronic kidney disease. According to the company, the NDA resubmission is set for mid-2024, with regulatory approval expected within six months.
• In November 2023, Sanofi launched "The 1 Pledge" movement, a nationwide education campaign. The "The 1 Pledge" project will be led by well-known celebrities, including artist and philanthropist Usher Raymond IV, whose child was diagnosed with type 1 diabetes at age.
• In April 2023, Sanofi, a multinational pharmaceutical and healthcare corporation, announced the completion of its acquisition of ProventionBio, Inc., a biopharmaceutical firm. The acquisition adds TZIELD (teplizumab-mzwv), a novel, fully owned, first-in-class medication for type 1 diabetes, to Sanofi's core asset portfolio in General Medicines, accelerating the company's strategy transition toward differentiated medicines.
• In August 2020, Mylan N.V. (acquired by Viatris, a global pharmaceutical and healthcare corporation), and Biocon Biologics India Ltd., a subsidiary of Biocon , a biopharmaceutical company, announced the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen formats. Semglee is approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes, as well as adults with type 2 diabetes.